DERM - Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript

2025-03-26 19:10:04 ET

Journey Medical Corporation (DERM)

Q4 2024 Results Conference Call

March 26, 2025 04:30 PM ET

Company Participants

Jaclyn Jaffe - Senior Director, Corporate Operations

Claude Maraoui - Co-Founder, President and CEO

Joseph Benesch - Chief Financial Officer

Louis Donati - Director of Market Access

Srini Sidgiddi - Vice President, Research and Development

Ramsey Alloush - General Counsel and Corporate Secretary

Conference Call Participants

Thomas Flaten - Lake Street Capital Markets

Scott Henry - AGP

Brandon Folkes - Rodman & Renshaw

Jason Wittes - Roth Capital

Kalpit Patel - B. Riley Securities

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's 2024 Financial Results and Corporate Update Conference Call. [Operator Instructions]

I would now like to turn the call over to Jaclyn Jaffe, the Company's Senior Director of Corporate Operations. Please go ahead.

Jaclyn Jaffe

Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; and Joseph Benesch, Chief Financial Officer. Joining for the Q&A portion of the call will be Ramsey Alloush, General Counsel and Corporate Secretary; Dr. Srini Sidgiddi, Vice President of Research and Development; and Louis Donati, Director of Market Access.

During this call, management will be making forward-looking statements, including statements that address, among other things, Journey Medical's expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements.

For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today, and the company's press release that accompanies this call, particularly the cautionary statements in it....

For further details see: